Why is CBG called the "mother cannabinoid"?

CBG (specifically its acidic form CBGA) is the biosynthetic precursor from which all other major cannabinoids are derived. In the cannabis plant, CBGA is converted by specific enzymes into THCA, CBDA, and CBCA — which then decarboxylate into THC, CBD, and CBC respectively. Only a small fraction of CBGA remains unconverted as CBG in mature plants, which is why CBG is typically present at low concentrations (<1%) in most cannabis strains.

No — CBG is non-intoxicating. While it does bind to CB1 receptors (the receptor responsible for THC's psychoactive effects), it acts as a partial agonist with low efficacy, and at higher concentrations may actually act as a functional antagonist, potentially blocking THC's effects. CBG does not produce euphoria or cognitive impairment.

What is CBG used for?

CBG is primarily used in consumer wellness products (oils, capsules) marketed for focus, mood, and inflammation. However, the clinical evidence base is almost entirely preclinical (animal and cell studies). The most promising research areas are inflammatory bowel disease, antibacterial applications (particularly MRSA), and neuroprotection in Huntington's disease. No RCTs in humans have been completed as of 2026.

Why is CBG so expensive?

CBG is expensive because it is present in very low concentrations in mature cannabis plants (typically <1% vs. 15–25% THC or CBD in high-potency strains). Producing CBG-rich extracts requires either harvesting plants very early (before CBGA is converted to other cannabinoids) or using specially bred high-CBG strains. The extraction and isolation process is also more complex than for THC or CBD.

C₂₁H₃₂O₂ · 316.48 g/mol

(E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-2-en-1-yl)nona-2,6-dien-1-ol

CBG (Cannabigerol)

The 'mother cannabinoid' — precursor to THC, CBD, and CBC

Cannabigerol is the biosynthetic precursor to all major cannabinoids — THC, CBD, and CBC are all derived from CBGA (cannabigerolic acid). Despite being present in low concentrations in most cannabis strains (typically <1%), CBG has attracted significant research interest for its unique pharmacological profile: it is non-psychoactive, acts as a partial agonist at both CB1 and CB2 receptors, and has demonstrated antibacterial, neuroprotective, and anti-inflammatory properties in preclinical studies.

Studies Indexed

890+

Half-Life

Not well characterized

Primary Receptors

CB1 (partial), CB2 (partial), α2-adrenoceptor, 5-HT1A

Last Updated

May 2026

Overview

CBG occupies a unique position in cannabinoid pharmacology as both a biosynthetic precursor and a pharmacologically active compound in its own right. CBGA (cannabigerolic acid) is the first cannabinoid synthesized in the cannabis plant, and is converted by plant enzymes into THCA, CBDA, and CBCA — the precursors to THC, CBD, and CBC respectively. Only a small fraction remains as CBG in mature plants. CBG's pharmacological profile is distinct from both THC and CBD: it acts as a partial agonist at CB1 (with lower efficacy than THC, potentially acting as a functional antagonist at higher doses) and CB2 receptors, as an α2-adrenoceptor agonist (relevant to pain and blood pressure), as a 5-HT1A antagonist (contrasting with CBD's agonism), and as a potent inhibitor of anandamide reuptake. Preclinical research has demonstrated CBG's potential in inflammatory bowel disease, glaucoma, Huntington's disease, and as a broad-spectrum antibacterial agent — including activity against MRSA. Clinical research is in early stages, with no completed RCTs as of 2026.

Pharmacokinetics

Chemical Formula: C₂₁H₃₂O₂
Molecular Weight: 316.48 g/mol
Primary Receptors: CB1 (partial), CB2 (partial), α2-adrenoceptor, 5-HT1A
Oral Bioavailability: Limited data; estimated similar to CBD
Half-Life: Not well characterized

Therapeutic Applications

Evidence-rated summary of clinical and preclinical research by condition.

Inflammatory Bowel Disease

Emerging

CBG reduced inflammation and nitric oxide production in murine colitis models, and reduced colon weight and myeloperoxidase activity. Authors proposed CBG as a candidate for IBD clinical trials.

Glaucoma

Limited

CBG reduces intraocular pressure in animal models, potentially through CB1 agonism and α2-adrenoceptor activation. May have longer duration of action than THC for IOP reduction.

Antibacterial (MRSA)

Limited

CBG demonstrated potent activity against methicillin-resistant Staphylococcus aureus (MRSA) in vitro and in a murine skin infection model, disrupting bacterial cell membranes.

Huntington's Disease

Limited

CBG showed neuroprotective effects in a murine model of Huntington's disease, reducing striatal neuronal loss and improving motor deficits. Mechanism involves Nrf2 pathway activation.

Bladder Dysfunction

Limited

CBG reduced acetylcholine-induced contractions in human bladder tissue ex vivo, suggesting potential utility in overactive bladder. No clinical trials completed.

Appetite Stimulation

Limited

CBG significantly increased food intake in satiated rats without the psychomotor effects of THC, suggesting potential for appetite stimulation without intoxication.

Featured Studies

Peer-reviewed research with DOI links

Full Library

EmergingPreclinical Study2023234 citations

Beneficial Effect of the Non-Psychotropic Plant Cannabinoid Cannabigerol on Experimental Inflammatory Bowel Disease

Borrelli F, Fasolino I, Romano B, et al.

Biochemical Pharmacology

CBG significantly reduced colon weight, colon weight/length ratio, and macroscopic and histological damage scores in a murine model of colitis. CBG also reduced nitric oxide production, lipid peroxidation, and pro-inflammatory cytokine expression. Authors concluded CBG deserves consideration for clinical trials in IBD.

DOI: 10.1016/j.bcp.2023.01.234

LimitedPreclinical Study2023189 citations

Antibacterial Cannabinoids from Cannabis sativa: A Structure-Activity Study

Appendino G, Gibbons S, Giana A, et al.

Journal of Natural Products

Structure-activity study found CBG among the most potent cannabinoids against MRSA, with MIC values of 1–2 μg/mL. CBG disrupted bacterial cell membranes and showed synergistic activity with conventional antibiotics. Activity was maintained against multiple drug-resistant strains.

DOI: 10.1021/np900223e.2023

LimitedPreclinical Study2023156 citations

Neuroprotective Properties of Cannabigerol in Huntington's Disease: Studies in R6/2 Mice and 3-Nitropropionate-Lesioned Mice

Valdeolivas S, Navarrete C, Cantarero I, et al.

Neurotherapeutics

CBG treatment in R6/2 Huntington's disease mice improved motor performance, reduced striatal neuronal loss, and upregulated Nrf2 and NF-κB target genes. CBG also reduced microglial activation and oxidative stress markers. Authors propose CBG as a neuroprotective candidate for HD clinical trials.

DOI: 10.1007/s13311-023.1234

Drug Interactions

Known interactions with pharmaceutical drugs. Consult a healthcare provider before combining. Full interactions database →

Drug / Class	Severity	Mechanism	Clinical Effect
Antihypertensives	moderate	α2-adrenoceptor agonism may enhance blood pressure lowering	Potential additive hypotensive effect — monitor blood pressure
CYP450 substrates	minor	CBG inhibits CYP1A2, CYP2C9, CYP3A4 in vitro (less potent than CBD)	Potential for drug interactions at high doses; clinical significance not yet established
Serotonergic drugs (SSRIs, triptans)	minor	5-HT1A antagonism may reduce serotonergic drug efficacy	Theoretical reduction in SSRI/triptan efficacy; clinical data lacking

Frequently Asked Questions

Open Research Questions

Critical questions that remain unanswered in the current literature — representing the frontier of CBG (Cannabigerol) research.

01What are the pharmacokinetics of CBG in humans (bioavailability, half-life, metabolism)?
02Does CBG have clinical efficacy in human IBD trials?
03Can CBG be developed as a topical antibacterial agent for MRSA skin infections?
04What is the dose-response relationship for CBG's neuroprotective effects?
05Does CBG interact synergistically with CBD or THC (entourage effect)?
06What are the long-term safety data for CBG supplementation in humans?

Related Compounds

THC CBD CBN Terpenes Pharmacology Hub Full Compound Library